Inhibitory effect of vascular endothelial growth factors-targeted small interfering RNA on proliferation of gastric cancer cells

Table 1 Sequence of designed siRNA

siRNA	Sense strand	Antisense strand
SiRNA1	5’-GAUCAAACCUCACC AAGGCUU-3’	5’-GCCUUGGUGAGG UUUGAUCUU-3’
siRNA2	5’-GGAGUACCCUGAUG AGAUCUU-3’	5’-GAUCUCAUCAGG GUACUCCUU-3’
siRNASCR	5’-GCGUAACGCGGGAA UUUACUU-3’	5’-GUAAAUUCCCGC GUUACGCUU-3’

Table 2 Data of MTT assay after transfected by siRNA for 24 h (mean ± SD, n = 5)

Grouping	Absorption	Inhibitory rate (%)
Untreaded group	0.444 ± 0.027	-
Lipofectin group	0.440 ± 0.029	0.9
siRNASCR group	0.438 ± 0.023	1.3
siRNA1-100 nm group	0.377 ± 0.024b	15.1
siRNA1-200 nm group	0.279 ± 0.023d	37.2
siRNA1-400 nm group	0.383 ± 0.022b	13.7
siRNA1-1000 nm group	0.395 ± 0.040	11.0
siRNA2-100 nm group	0.379 ± 0.031b	14.6
siRNA2-100 nm group	0.278 ± 0.025d	37.3
siRNA2-100 nm group	0.383 ± 0.026b	13.7
siRNA2-100 nm group	0.394 ± 0.033	11.3

^bP < 0.01,

^dP < 0.001 vs the lipofectin group.

Table 3 Change of cell cycle measured by flow cytometry

Group	G0/G1 phase (%)	S phase (%)	G2/M phase (%)
Untreaded group	58.37	39.52	2.11
Lipofectin group	58.76	40.18	1.06
siRNASCR group	58.23	41.34	0.43
siRNA1 group	75.04b	17.82b	7.14
siRNA2 group	76.52b	16.73b	6.75

^bP < 0.01 vs untreated group.

Table 4 Data of absorbance (AVEGF/AGAPDH) (mean ± SD, n = 3)

Group	AVEGF/AGAPDH
Normal control group	0.856 ± 0.009
Lipofectin group	0.834 ± 0.020
siRNASCR group	0.815 ± 0.017
siRNA1 group	0.456 ± 0.030b
siRNA2 group	0.468 ± 0.019b

^bP < 0.01 vs lipofectin group.

Table 5 Change of VEGF protein in supernatant (mean ± SD, n = 3)

Group	VEGF (p/ng per L)	Inhibition efficiency (%)
Normal control group	414.0 ± 61.5	-
Lipofectin group	366.3 ± 25.5	-
siRNASCR group	350.0 ± 25.7	4.46
siRNA1 group	164.6 ± 22.7b	55.1
siRNA2 group	166.3 ± 26.6b	54.6

^bP < 0.01 vs lipofectin group; Inhibition efficiency = (lipofectin group- siRNA group)/lipofectin group.